BeOne Medicines

Ultime notizie

Titoli nella lingua originale della fonte.

• ONC Maintained by JP Morgan -- Price Target Raised to $445 (si apre in una nuova scheda)

  GuruFocus · 1 ott 2026

• BeOne Medicines (NASDAQ:ONC) Stock Price Target Raised at JPMorgan Chase & Co. (si apre in una nuova scheda)

  MarketBeat · 1 ott 2026

• BeOne Medicines price target raised to $445 from $425 at JPMorgan (si apre in una nuova scheda)

  TipRanks · 1 ott 2026

• Biotech Leader BeOne Medicines Poised To Hit Early Buy Points (si apre in una nuova scheda)

  Investor's Business Daily · 1 ott 2026

• BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Stock Has Consensus Target Price of $402.71 (si apre in una nuova scheda)

  MarketBeat · 1 ott 2026

• Form 144 BEONE MEDICINES LTD. For: 1 October By Investing.com (si apre in una nuova scheda)

  Investing.com Canada · 1 ott 2026

• BeOne Medicines (NASDAQ:ONC) Insider Sells $11,318,704.12 in Stock (si apre in una nuova scheda)

  MarketBeat · 30 set 2026

• After exercising options, BeOne Medicines (ONC) scientific advisory chair sold 31,028 depositary shares. (si apre in una nuova scheda)

  Stock Titan · 30 set 2026

• An officer proposes selling $407K in vested stock grants at BeOne Medicines (ONC). (si apre in una nuova scheda)

  Stock Titan · 30 set 2026

• BeOne Medicines Ltd (6160) Receives a Buy from DBS (si apre in una nuova scheda)

  The Globe and Mail · 29 set 2026

• BeOne Medicines Advances BGB-58067 Tablet Study, Sharpening Early-Stage Investor Focus (si apre in una nuova scheda)

  TipRanks · 28 set 2026

• Josh Schwartz Marks His Final Day at BeOne Medicines (si apre in una nuova scheda)

  Oncodaily · 27 set 2026

• BeOne Medicines (ONC) Rebrand Puts Its Growth Story In Focus On A Higher Fair Value (si apre in una nuova scheda)

  Simply Wall Street · 26 set 2026

• BeOne Medicines Advances Phase 3 Liver Cancer Trial With BGB-B2033 (si apre in una nuova scheda)

  TipRanks · 23 set 2026

• Sonrotoclax Safety Study Completion Signals Next Steps for BeOne Medicines (si apre in una nuova scheda)

  TipRanks · 21 set 2026

• ONC Q2 2026 Earnings: Reported EPS of $13.84 as Shares Edge Lower - Earnings Volatility Report (si apre in una nuova scheda)

  dars.gov.et · 21 set 2026

• BeOne Medicines (ONC) insiders exercise options for 30,768 ADS (si apre in una nuova scheda)

  Stock Titan · 18 set 2026

• BeOne Medicines at Morgan Stanley conference: brukinsa, pipeline drive growth (si apre in una nuova scheda)

  Investing.com UK · 14 set 2026

• The Bull Case For BeOne Medicines (ONC) Could Change Following US-Backed HER2 Regimen And Onshoring Deal (si apre in una nuova scheda)

  Yahoo Finance · 4 set 2026

• BeOne (ONC) Secured a Pharmaceutical-Tariff Exemption After More than $1B of U.S. Manufacturing Investment. Are the Pricing Concessions Worth It? (si apre in una nuova scheda)

  Yahoo Finance · 4 set 2026

• BeOne Medicines (ONC) Holds Steady Near $362 Within Defined Trading Range - BPI Bear Correction (si apre in una nuova scheda)

  siam.in · 3 set 2026

• BeOne (ONC) accounting chief sells ADS to cover RSU taxes (si apre in una nuova scheda)

  Stock Titan · 3 set 2026